Deepmirror Ltd

Drug Discovery (DD) involves costly-and-lengthy experimental cycles to design novel drugs, synthesise them and then test their properties (e.g.toxicity/absorption/target-binding). DD success rate is extremely low: only 1:10,000 clinical-trial drug-candidates are FDA approved\[Boyd,2021\]. Predicting drug-properties is key in de-risking of assets before ex...

Nuclera is a world-leader in the nascent space of active-matrix thin-film-transistor digital-microfluidics. Nuclera is developing a cutting-edge rapid protein prototyping/synthesising platform, eProteinDiscovery(TM). Industry partners (CROs/SMEs/large-pharma) have shown a desire to have fast protein access, automated and in-house to address this key chall...

Protein kinases are involved in almost all bodily function and changes in their activity can give rise to cancer and other diseases. Nevertheless, few drugs exist that target kinases as they are considered "difficult to drug" by leading experts. Recently, DNA Encoded Small Molecule Libraries (DELs) have attracted attention due to their ability to enable s...

RNA therapeutics will change the standard of care for many diseases, transitioning from rare to chronic diseases, and actualize personalized medicine for millions of patients. Advances in generating, purifying and delivery of RNA mean drugs can be cost-effective and target new pathways. As a disruptive therapeutic technology, small research groups and bio...

In gene technologies lies the future of human and environmental health. Edited genes and other gene-based therapeutics will create more nutritious and environmentally friendly crops and enable the fight against debilitating diseases. Recently, new tools such as CRISPR/Cas9 greatly simplified gene editing and enabled us to perform genetic changes more prec...